Nivolumab and its use in the second-line treatment of metastatic urothelial cancer

Daniele Raggi, Andrea Necchi, Patrizia Giannatempo

Research output: Contribution to journalArticle

Abstract

Nivolumab is a fully human monoclonal antibody blocking PD-1 with demonstrated effectiveness against metastatic urothelial carcinoma. In this review, we describe the pharmacological properties of nivolumab and the treatment of metastatic urothelial carcinoma with this checkpoint inhibitor after the failure of first-line platinum-based chemotherapy. Cancer immunotherapy by checkpoint inhibition offers potential to prolong patient survival with well manageable toxicity although serious immune-related adverse events may occur. The overall response rate to nivolumab after first-line chemotherapy is about 20%. Patients unfit for cisplatin may benefit from first-line cancer immunotherapy. It remains unclear which patient will respond and PD-1/PD-L1 expression alone is not a sufficiently reliable predictive biomarker.

Original languageEnglish
Pages (from-to)2683-2690
Number of pages8
JournalFuture Oncology
Volume14
Issue number26
DOIs
Publication statusPublished - Nov 2018

Fingerprint

Immunotherapy
Carcinoma
Drug Therapy
Neoplasms
Platinum
Cisplatin
Therapeutics
Biomarkers
Monoclonal Antibodies
Pharmacology
Survival
nivolumab

Cite this

Nivolumab and its use in the second-line treatment of metastatic urothelial cancer. / Raggi, Daniele; Necchi, Andrea; Giannatempo, Patrizia.

In: Future Oncology, Vol. 14, No. 26, 11.2018, p. 2683-2690.

Research output: Contribution to journalArticle

Raggi, Daniele ; Necchi, Andrea ; Giannatempo, Patrizia. / Nivolumab and its use in the second-line treatment of metastatic urothelial cancer. In: Future Oncology. 2018 ; Vol. 14, No. 26. pp. 2683-2690.
@article{bcd021a808d14c388bc09efc79b7d299,
title = "Nivolumab and its use in the second-line treatment of metastatic urothelial cancer",
abstract = "Nivolumab is a fully human monoclonal antibody blocking PD-1 with demonstrated effectiveness against metastatic urothelial carcinoma. In this review, we describe the pharmacological properties of nivolumab and the treatment of metastatic urothelial carcinoma with this checkpoint inhibitor after the failure of first-line platinum-based chemotherapy. Cancer immunotherapy by checkpoint inhibition offers potential to prolong patient survival with well manageable toxicity although serious immune-related adverse events may occur. The overall response rate to nivolumab after first-line chemotherapy is about 20{\%}. Patients unfit for cisplatin may benefit from first-line cancer immunotherapy. It remains unclear which patient will respond and PD-1/PD-L1 expression alone is not a sufficiently reliable predictive biomarker.",
author = "Daniele Raggi and Andrea Necchi and Patrizia Giannatempo",
year = "2018",
month = "11",
doi = "10.2217/fon-2017-0735",
language = "English",
volume = "14",
pages = "2683--2690",
journal = "Future Oncology",
issn = "1479-6694",
publisher = "Future Medicine Ltd.",
number = "26",

}

TY - JOUR

T1 - Nivolumab and its use in the second-line treatment of metastatic urothelial cancer

AU - Raggi, Daniele

AU - Necchi, Andrea

AU - Giannatempo, Patrizia

PY - 2018/11

Y1 - 2018/11

N2 - Nivolumab is a fully human monoclonal antibody blocking PD-1 with demonstrated effectiveness against metastatic urothelial carcinoma. In this review, we describe the pharmacological properties of nivolumab and the treatment of metastatic urothelial carcinoma with this checkpoint inhibitor after the failure of first-line platinum-based chemotherapy. Cancer immunotherapy by checkpoint inhibition offers potential to prolong patient survival with well manageable toxicity although serious immune-related adverse events may occur. The overall response rate to nivolumab after first-line chemotherapy is about 20%. Patients unfit for cisplatin may benefit from first-line cancer immunotherapy. It remains unclear which patient will respond and PD-1/PD-L1 expression alone is not a sufficiently reliable predictive biomarker.

AB - Nivolumab is a fully human monoclonal antibody blocking PD-1 with demonstrated effectiveness against metastatic urothelial carcinoma. In this review, we describe the pharmacological properties of nivolumab and the treatment of metastatic urothelial carcinoma with this checkpoint inhibitor after the failure of first-line platinum-based chemotherapy. Cancer immunotherapy by checkpoint inhibition offers potential to prolong patient survival with well manageable toxicity although serious immune-related adverse events may occur. The overall response rate to nivolumab after first-line chemotherapy is about 20%. Patients unfit for cisplatin may benefit from first-line cancer immunotherapy. It remains unclear which patient will respond and PD-1/PD-L1 expression alone is not a sufficiently reliable predictive biomarker.

U2 - 10.2217/fon-2017-0735

DO - 10.2217/fon-2017-0735

M3 - Article

C2 - 29927336

VL - 14

SP - 2683

EP - 2690

JO - Future Oncology

JF - Future Oncology

SN - 1479-6694

IS - 26

ER -